Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Pentazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 9/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.83 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.83 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.83 |
| ▸ | EBP | Q15125 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Pentazocine SCHEMBL42094 | 1.00 | SIGMAR1 (0.83) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| Pentazocine SCHEMBL16107180 | 1.00 | SIGMAR1 (0.83) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| Pentazocine SCHEMBL7865847 | 0.94 | SIGMAR1 (0.83) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| Rel-Pentazocine SCHEMBL135685 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| (+)-Pentazocine SCHEMBL680675 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| Pentazocine SCHEMBL2493 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| (+)-Pentazocine SCHEMBL4376337 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| (+)-Pentazocine SCHEMBL16220021 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| (+)-Pentazocine SCHEMBL22865258 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 | |
| (+)-Pentazocine SCHEMBL18672553 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115737571-B | Pentazocine Xin Zhiji and preparation method and application thereof | 广州市力鑫药业有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-115737571-A | Pentazocine preparation and preparation method and application thereof | 广州市力鑫药业有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10463640-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-10441558-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-10-15 | — | — | US | disclosed |
| US-10322101-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-06-18 | — | — | US | disclosed |
| EP-3459535-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2019-03-27 | — | — | EP | disclosed |
| US-20180360785-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-12-20 | — | — | US | disclosed |
| US-20180338969-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-11-29 | — | — | US | disclosed |
| US-20180250289-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-09-06 | — | — | US | disclosed |
| US-20150157626-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | NEOVACS S.A. (FR) | 2015-06-11 | — | — | US | disclosed |
| US-8992891-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2015-03-31 | — | — | US | disclosed |
| CN-101883561-B | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2014-07-30 | — | — | CN | disclosed |
| EP-2609916-A1 | New therapeutic approaches for treating CMT and related disorders | Pharnext (FR) | 2013-07-03 | — | — | EP | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |